Key Points
- Insider selling: Chairman Jurgi Camblong sold 24,381 SOPHiA GENETICS shares at an average of $6.29, receiving approximately $153,356. He retained 3.51 million shares, and the transaction was made under a pre-arranged Rule 10b5-1 plan.
- Financial performance: SOPHiA GENETICS reported quarterly revenue of $21.69 million, exceeding expectations, but posted an EPS loss of $0.27 versus the $0.23 consensus estimate. Analysts expect a full-year loss of approximately $0.58 per share.
- Market and analyst view: The stock opened at $5.57, with a one-year range of $2.92 to $6.77. Analyst sentiment is mixed but averages a “Hold” rating, with a consensus price target of $9.00 and individual targets ranging from $8 to $12.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 5,000 shares of the firm's stock in a transaction on Monday, July 27th. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00. Following the completion of the sale, the insider owned 223,387 shares in the company, valued at $1,264,370.42. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Philippe Menu also recently made the following trade(s):
- On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $28,500.00.
- On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total value of $38,147.88.
- On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total value of $27,500.00.
- On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.95, for a total value of $24,750.00.
SOPHiA GENETICS Price Performance
Shares of SOPH stock opened at $5.57 on Wednesday. SOPHiA GENETICS SA has a 12 month low of $2.92 and a 12 month high of $6.77. The company has a market capitalization of $467.27 million, a P/E ratio of -10.71 and a beta of 0.96. The stock has a 50 day moving average of $5.42 and a two-hundred day moving average of $5.09. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). The firm had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.58 EPS for the current year.
Analyst Ratings Changes
A number of brokerages have recently issued reports on SOPH. BTIG Research restated a "buy" rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a research note on Monday, June 15th. HC Wainwright began coverage on shares of SOPHiA GENETICS in a report on Monday, July 20th. They set a "buy" rating and a $12.00 price objective for the company. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, SOPHiA GENETICS presently has an average rating of "Hold" and a consensus price target of $9.00.
Check Out Our Latest Stock Analysis on SOPH
Hedge Funds Weigh In On SOPHiA GENETICS
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at $49,000. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS in the third quarter valued at $49,000. First Dallas Securities Inc. acquired a new position in SOPHiA GENETICS during the first quarter worth $50,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS during the fourth quarter worth $54,000. Finally, XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS during the fourth quarter valued at $55,000. Institutional investors own 31.59% of the company's stock.
About SOPHiA GENETICS
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
